Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood pressure drug reverse heart scarring after aortic repair?

NCT ID NCT06150560

Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This trial tests whether losartan, a common blood pressure medication, can reduce scarring in the heart's main pumping chamber and improve exercise capacity in adults who had surgery to repair coarctation of the aorta. Participants will take losartan, amlodipine, or a placebo daily for a year. The study uses MRI scans and exercise tests to measure changes in heart tissue and fitness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Losartan (an angiotensin-II receptor blocker, also known as Cozaar), compared against amlodipine and placebo
What this could lead to
If successful, losartan could become a standard treatment to reduce heart muscle scarring and improve exercise tolerance in people who had coarctation repair, potentially lowering long-term cardiovascular risks.
What could go wrong
This is a phase 3 trial, but results are not yet known. The drug may not outperform amlodipine or placebo, and side effects like dizziness, high potassium, or kidney issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * B/S1 hypertension * SBP 100-139 average based on 3 office measurements. * Age 18 or Older * Previous COA Repair Exclusion Criteria: * Currently on beta blocker (BB) therapy * Pregnancy/lactating * eGFR\<30 * Hyperkalemia (serum potassium \>5.5mmol/L) * Severe Aortic or Mitral valve stenosis or regurgitation * Epicardial CAD diagnosis * Received antihypertensive medications within the past year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coarctation of aorta are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aorta coarctation hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coarctation of aorta High blood pressure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.